Oncology Articles

AR-V7 Biomarker Test Remains on the Wish List for CRPC
The use of biomarkers in genitourinary cancers offers exciting potential in understanding which patients may do better with androgen-targeting therapies.
Researchers have concluded from an analysis of multiple studies that the fecal immunochemical test has high overall diagnostic accuracy for screening asymptomatic patients at an increased risk for colorectal cancer (CRC) and moderate accuracy for diagnosing advanced neoplasia (AN).
Manuel Hidalgo, MD, discusses his insight on the growth of genetic testing in CRC.
Crizotinib Induces High Response Rates in Pediatric ALCL, IMT
In a small study of pediatric patients with relapsed/refractory ALK-positive anaplastic large cell lymphoma, treatment with 165 mg/m2 of crizotinib (Xalkori) was associated with an overall response rate of 83%
Drake Discusses Immunomodulatory Therapies
Charles Drake, MD, PhD, shares his insight on the promise and challenges with immunomodulatory drugs, and immune-activating agents in prostate cancer.
EGFR-Mutant NSCLC Treatment Paradigm on Verge of Disruption
Monotherapy with a tyrosine kinase inhibitor is the frontline standard of care for patients with advanced EGFR-mutant non–small cell lung cancer, with 3 currently approved agents: erlotinib, gefitinib, and afatinib.
Gilteritinib, a selective TKI against FLT3, demonstrated a favorable safety profile and consistent FLT3 inhibition in adults with relapsed/refractory acute myeloid leukemia.
Expert Explains Approaches in Non-Driver NSCLC
Lyudmila A. Bazhenova, MD, discusses the non-driver NSCLC population, the treatment strategies available for them, and challenges physicians continue to face with this subgroup of patients.
FDA Approves Olaparib Tablets for Ovarian Cancer
The FDA has approved olaparib tablets as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
FDA Approves Inotuzumab Ozogamicin for ALL
The FDA has approved inotuzumab ozogamicin for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Publication Bottom Border
Border Publication